Focused On-demand Library for Serine/threonine-protein kinase TBK1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UHD2

UPID:

TBK1_HUMAN

Alternative names:

NF-kappa-B-activating kinase; T2K; TANK-binding kinase 1

Alternative UPACC:

Q9UHD2; A8K4S4; Q8IYV3; Q9NUJ5

Background:

Serine/threonine-protein kinase TBK1, also known as NF-kappa-B-activating kinase, plays a pivotal role in inflammatory responses, antiviral immunity, and autophagy. It activates IRFs and NF-kappa-B, contributing to the transcription of pro-inflammatory and antiviral genes. TBK1's involvement in phosphorylating various proteins underscores its multifunctional nature in cellular signaling pathways.

Therapeutic significance:

TBK1's association with diseases such as Glaucoma 1, open angle, P, Frontotemporal dementia and/or amyotrophic lateral sclerosis 4, and herpes-specific encephalopathy highlights its potential as a therapeutic target. Understanding TBK1's role could pave the way for novel treatments for these conditions, emphasizing the importance of research in this area.